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Sham (n=lO) Radiated (n=lZ) p Value 
Plaque Area (mm2) 1.05 * 0.6 1.6*0.5 < 0.02 
Macrophages (% RAM 11) 14.6 * 9.8 35.1 * 9.1 < 0.0001 
SMC (%I?.-actin) 19.9 * 15.2 8.7 f 10.6 < 0.001 
MMP-1 (% area) 41.2 + 23.4 26.5 t 9.4 0.01 
Conclusion: In this atherosclerotic rabbit model, radiation was associated with 
decreased smooth muscle cell density, increased infiltration of macrophages and 
Increased plaque burden. Metalloprotease 1 was also over-expressed in the radiated 
arteries. Thus, special care should be taken in hypercholesterolemic patients treated with 
VBT. 
1152-126 Angiotensin Converting Enzyme Inhibitor Therapy 
Reduces the Vascular Oxidative State in Normotensive 
Patients With Newly Diagnosed Type 2 Diabetes 
Mellitus 
BobbvV. Khan, Rekha G. Menon. Stamatios Lerakis, Emory University School of 
Medicine, Atlanta, GA 
Background: The increase an the vascular &dative state and production of reactive oxy- 
gen species are significant in the pathogenesis of atherosclerosis. The therapeutic use of 
renin-angiotensin system (RAS) antagonists, including ACE inhibitors, results in a signifi- 
cant reduction of cardiovascular events in patients with coronary artery disease. Recent 
outcome studies demonstrate that these agents may have vascular benefits independent 
of blood pressure reduction. Methods: We followed 33 normotensive subjects 
(female:l8, male:15) with newly diagnosed (less than one year) type II diabetes mellitus. 
These patients were under fair metabolic control (glycosylated hemoglobin < 7.5%) and 
with normal renal function and no evidence of overt proteinuria. The subjects were 
started on the ACE inhibitor quinapril 20 mglday for 4 weeks. Serum samples were 
drawn. The elythrocyte superoxide dismutase (E-SOD) activity and lag time for LDL oxi- 
dation were measured. 
Results: Treatment with quinaprfl significantly increased E-SOD activity (pre: 543+70; 
post: 812+98 U/gHb, p<O.O5). Furthermore, quinapril therapy significantly enhanced lag 
time for LDL oxidation in these subjects (pre: 63_+11; post: SF&l0 sec. pcO.O5), suggest- 
ing an increased resistance of LDL modification in the vasculature. No changes in sys- 
tolic blood pressure (pre: 11&l 1; post: 11&8 mm Hg. NS). LDL cholesterol, or 
metabolic control were noted with quinapril therapy. Conclusions: Administration of ACE 
inhibitor therapy Improves the vascular oxidative state in patients with newly diagnosed 
Type II diabetes mellitus. Furthermore, these effects appear to be independent of blood 
pressure reduction or changes in the metabolic control of diabetes mellitus. 
1152-127 Roxithromycin Inhibits Plaque Formation Induced by 
Recurrent Lipopolysaccharide Inflammation In Vivo 
Markus G. Enqelmann, Constanze V. Redl, Sigrid Nikol, University of Munich, Klinikum 
Grosshadern, Munich, Germany, University Hospital, University of Muenster, Muenster, 
Germany 
Alms: Recently we demonstrated increased plaque formation occurred after repetitive 
LPS application in cholesterol-fed animals. Thus, repeated local infection by microorgan- 
~sms may contribute to atherogenesis through specific bacterial products such as LPS. In 
the current study we assessed the effect of macrolide treatment on prevention of LPS- 
induced atherogenesis in the absence of a bacterial infection. 
Methods and results: Rabbits (n=14) were fed a cholesterol-enriched diet. All animals 
were treated with a single perivascular injection of bacterial lipopolysaccharide (LPS) 
placed next to auncular, carotid and femoral arteries and sodium chloride placed next to 
the contralateral arteries with repeated perivascular injectlons over 90 days. 5 days after 
initial LPS or sodium chloride treatment the animals were randomized to two groups. 
Group A animals were treated with roxithromycin 40 mg/kg/d, gioup B animals served as 
control. Vascular tissues (n=41 treated segments) were analyzed using morphomehy at 
histology, and using lmmunohistochemistry to detect macrophages. lymphocytes, vascu- 
lar smooth muscle cells. Repeated LPS application resulted in significant plaque forma- 
tion compared with control (Group B, plaque-area index 0.122+0.05 vs 0.029t0.02, 
p=O.OZ). The plaque induction effect of LPS was inhibited by long term roxithromycin 
treatment (Group A, plaque-area index 0.045*0.02. LPS treatment, vs 0.017+0.01, con- 
trol, p=O.O49). 
Conclusion: The significant Increase I” plaque formation after repeated perivascular LPS 
application in cholesterol-fed animals can be inhibited by long term treatment using 
roxithromycin. The anti-inflammatory effect of macrolides may contribute to reduced 
atherogenesis through specific bacterial products such as LPS. 
1152-128 Enhancement of Inhibitory Effects of Glycoprotein Ilb/ 
llla Antagonists in Patients With Diabetes: Effects of 
Glycation on the Kinetics of Fibrinogen Binding 
Fnedetike K. Keatinq, Burton E. Sobel. David J. Schneider, University of Vermont, 
Burlington, VT 
Background: Glycoprotem (GP) Ilb-llla antagonists reduce subsequent cardiac events 
to a greater extent I” patients with diabetes. To identify mechanisms potentially responsi- 
ble, we characterized inhibitory effects of GP Ilb-llla antagonists and the kinetics of fibrin- 
ogen bindmg to platelets from patients with and without diabetes. 
Methods Blood was incubated with tlrofiban or eptlfibatide in vitro for 15 minutes. The 
capacity of platelets to bind fibrinogen was determlned with the use of flow cytometry. 
Kinetics of binding of I “s -labeled fibrinogen to platelets were characterized in response 
to 10 FM ADP. Glycation of platelet membrane proteins was determined with the fruc- 
tosamine assay. Results were compared in patients with HbAlc r 6.5% (diabetes), and 
those with HbAlc < 6.5% (no diabetes). 
Results The capacity of platelets to bind fibrinogen was inhibited to a greater extent by 
either tirofiban (50 @ml) or eptifibatide (1.5 pg/ml) in blood from 34 patients wtth corn- 
pared with 38 without diabetes. Tirofiban inhibited fibrmogen binding by 67 f 17 % in 
blood from patients with and by 53 + 19 % in blood from those without diabetes (p = 
0.002). Eptifibatide inhibited fibrinogen binding by 64 * 21% in blood from patients with 
and by 52 + 23% in blood from those without diabetes (p = 0.024). Total stimulated bind- 
ing of fibrinogen assessed with the use of flow cytometry or I ‘ss-fibrinogen was similar 10 
minutes to 60 minutes after addition of ADP. By contrast, after 5 minutes, platelets from 
patients with diabetes bound 39% less /‘s-fibrinogen (% bound 1”s-fibrinogen, diabetes 
= 0.44 t 0.22, n=ll; no diabetes = 0.72 f 0.31, 1~10; p = 0.03). Increased platelet mem- 
brane protein glycation was seen with samples from patients with diabetes. 
Conclusions Greater clinical benefits associated with GP Ilb-llla antagonists in patients 
with diabetes appear to reflect augmented inhibitory effects in those with diabetes. The 
augmentation is mediated, at least in part, by glycatlon of membrane proteins that slows 
the rate of binding of fibrinogen. 
1152-129 Identification of Apoptosis-Inducing Factor Expression 
in Human Coronary Artery Endothelial Cells and Its 
Upregulation by Ox-Low-Density Lipoprotein 
Wenauana Zhanq Madhu Shokeen, Dayuan Li, Jawahar L. Mehta, University of 
Arkansas for Medical Sciences, Little Rock, AR, Central Arkansas Veterans Healthcare 
System, Little Rock, AR 
Background:Apoptosls-inducing factor (AIF) is a potent caspase-independent pathway 
of cell death, initially characterized in HeLa cells (Nature 1999; 397:441-6). Since 
caspase inhibitors do not completely block apoptosis in human coronary artery endothe- 
lial cells (HCAECs). we hypothesized that AIF may be another pathway of apoptosis in 
these cells. This study was designed to examine the presence of AIF in HCAECs and its 
regulation by ox-LDL. 
Methods 8 Resu/ls: Cultured HCAECs were pre-treated with ox-LDL in different con- 
centrations (0-BOwg/ml) and for different time points (l-24 h). Western blot analysis was 
used to determine AIF expression using anti-human AIF goat anttbody. Reverse tran- 
scription-polymerase chain reaction with pactin as internal standard was performed 
(primers: sense-S-GGATCCTGGGGCCAGGGTACTGAT-3 and antisense- 5’- 
CTCGGGGAAGAGlTGAATCACTTC-3’). We also sequenced AIF gene by ABI 377 
DNA Sequencer. In the resting cells, faint but distinct AIF bands were detected in all 
HCAEC preparations. The gene sequence had 99% homology with neuronal and HeLa 
cell AIF gene. Ox-LDL treatment of HCAECs cells significantly induced the expression of 
AIF (mRNA and protein). Exposure of HCAECs cells to 50pg protein/ml ox-LDL resulted 
in maximal increase. Induction of expression was evident at 1 h, and became maximal at 
24 h. Treatment of HCAECs with actinomycin-D blocked ox-LDL-mediated increase m 
AIF expression. Z-VAD.fmk, the inhlbitor of caspase did not affect the expression of AIF 
induced by ox-LDL. 
Conclusions:This study shows that HCAECs express AIF. and ox-LDL upregulates the 
expression of this novel pathway of cell death. 
1152-130 Increased Concentrations of Interleukin-1 Receptor 
Antagonist Associated With Diabetes Mellitus and in 
the Vicinity of Coronary Plaques: A Sensitive Marker of 
Inflammation 
Atul Aqqarwal, David J. Schneider, Edward F. Terrien, Deborah A. Whitaker, Burton E. 
Sobel, Harold L. Dauerman. University of Vermont, Burlington. VT 
Background: lnflammat!on portends adverse outcomes after percutaneous coronary 
interventions (PCI). Interleukin-I receptor antagonist (IL-l Ra) accompanies release of 
interleukin-I by macrophages associated with atherosclerotic plaques. Interleukin-1 stim- 
ulates release of interleukin-6 (IL-6) and C-reactive protein (CRP). To determine whether 
local inflammation could be detected in coronary blood, the concentrations of IL-1Ra. IL- 
6, and CRP were measured in blood simultaneously from the coronary and femoral alter- 
ies. 
Methods: Concentrations of CRP (@ml), IL-6 (pgiml), and IL-1Ra (pg/ml) were deter- 
mined by ELISA in blood obtained in 75 patients before PCI from the femoral artery and 
from a guide catheter after engagement of the culprit coronary artery. Results were com- 
pared with the use of paired Student’s t-tests. 
Ftesulte: The majority (68%) of the patients studied had acute coronary syndromes 
(ACS), and 36% had elevation of cardiac markers. Despite substantial inter-individual 
variability, IL-1Ra was consistently greater (by 50) in coronary compared with peripheral 
blood (coronary = 595*388. peripheral=545*378; p=O.O03). IL-1Ra was greater in core- 
nary blood from those with marker positive ACS (by 47), marker negative ACS (by 48), 
and stable symptoms (by 44). Similar concentrations of CRP (coronary = 9.0515, periph- 
eral=9.5+14: p=O.4) and IL-6 (coronary = 6.4k9.9. penpheral=6.9+10; p=O.l) were seen 
in coronary and peripheral blood. The concentration of IL-1Ra was greater in patients 
with diabetes (n=Zl), both in coronary blood (diabetes = 748+492, no diabetes = 
538+325; p =O.OZ) and peripheral blood (diabetes = 709*510. no diabetes = 482*294; p 
=0.02). 
Conclusions: Concentrations of IL-1Ra are greater in blood obtained from the culprit 
coronary artery and in samples from patients with diabetes mellitus. IL-1 Ra may be use- 
ful for detecting and assessing the magnitude of local inflammation associated with cul- 
prit lesions. Greater concentrations of IL-1 Ra in patients with diabetes mellitus suggests 
a heightened inflammatory state that may contribute to accelerated atherogenesis in dia- 
betes. 
